Mark Mirochnick | Profiles RNS

Mark H. Mirochnick, MD

Professor

Boston University Chobanian & Avedisian School of Medicine

Pediatrics

Neonatology

MD, University of Vermont College of Medicine
BSc, Dickinson College

Websites

	Boston Medical Center Provider Profile
	ResearchGate
	Leap Profile
	Loop Frontiers

ORCID : 0000-0002-3600-1502

Mark Mirochnick, MD is Professor of Pediatrics and a member of the Division of Neonatology at Chobanian and Avedisian School of Medicine/Boston Medical Center. His main research activities involve investigating the pharmacology of HIV and TB drugs in newborns, infants, children and pregnant women. He has served as protocol chair, investigator and/or protocol pharmacologist on many international protocol teams in this area. He currently serves as co-chair of the US Perinatal HIV Guidelines Committee and is a member of the US Pediatric HIV Guidelines Committee and the WHO Pediatric Antiretroviral Working Group.

Section Director
Boston University Chobanian & Avedisian School of Medicine
Pediatrics
Neonatology

A 48 Week, Phase II, Open-Label, Multi-Cohort, Multicenter Study to Evaluate the Safety , Tolerability, Pharmacokinetics, and Antiviral Activity of GW433908/Ritonavir QD when Administered to HIV-1 Infected, Antiretrovitral Naive and Experienced, Pediatric
07/01/2002 - 06/30/2006 (PI)
GlaxoSmithKline, Inc.

Open-Label Multicenter Multiple Dose Phase III Study of the Population Pharmacokinetics of IV Synecid 7.5 mg/kg q8h in &5 Pediatric Patients
11/01/2001 - 10/31/2003 (PI)
Aventis Pharmaceuticals Inc

Investigation of CD11b Expression in Neonates Using New Laser Scanning Cytometer Technology
10/19/1999 - 09/30/2000 (PI)
CompuCyte Corporation

IMPAACT 2023: A Phase I Study of the Safety and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
07/01/2022 - 06/30/2025 (PI)
Johns Hopkins University ViiV Healthcare

IMPAACT Leadership Group - 2032 Protocol Chair (remdescivir)
07/01/2023 - 12/30/2023 (PI)
Johns Hopkins University National Institute o

LDR 01: LOC-IMPAACT Leadership Group: Mirochnick
01/01/2014 - 11/30/2023 (PI)
Johns Hopkins University National Institute o
5UM1AI068632-17

IMPAACT 2032: Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States
12/01/2021 - 06/30/2023 (PI)
Johns Hopkins University Gilead Sciences

?P1026S - IMPAACT 1026S Pharmacokinetic Properties of ARVs during Pregnancy and Postpartum
07/01/2021 - 12/31/2022 (PI)
Johns Hopkins University National Institute o
5UM1AI068632-17

Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
06/01/2020 - 11/30/2022 (PI)
Johns Hopkins University National Institute o
3UM1AI068632-14S2

Enhanced maternal and fetal PBPK models to predict drug exposures of novel oral and long-acting antivirals during pregnancy
08/09/2020 - 07/31/2022 (PI)
The Regents of the University of Calif., U.C. San Diego National Institute o
5R21HD102856-02

LDR09 - P1026s: Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy...
07/01/2019 - 06/30/2021 (PI)
Johns Hopkins University Gilead Sciences

IMPAACT 2007 - Phase I Safety and Pharmacokeneticks of Marviorc in HIV 1 Exposed Infants at Risk …
07/01/2016 - 12/31/2020 (PI)
Johns Hopkins University PHIVCO UK II Ltd

Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials
12/01/2012 - 11/30/2016 (PI)
Univ of California, San Francisco NIH-NIAID

Showing 10 of 21 results. Show All Results

Title

Yr	Title	Project-Sub Proj	Pubs
2008	Safety Pharmacokinetics &Efficacy of Artemether &Lumefantrine in Pregnant Women	1R34AI076610-01
2007	PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN PREGNANT HIV INFECTED WOMEN	2M01RR000533-39-8160	503
2007	ANTIRETROVIRAL DRUGS DURING PREGNANCY, SUBSTUDY OF PACTG P1025	2M01RR000533-39-8139	503
2007	PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20)	2M01RR000533-39-8144	503
2006	PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20)	5M01RR000533-38-5591	503
2006	ANTIRETROVIRAL DRUGS DURING PREGNANCY, HIV INFECTED WOMEN (SUB OF PACTG P1025)	5M01RR000533-38-5584	503
2006	Antiretroviral Pharmacology/Lactating Mother/Infants	5R21HD051470-02	1
2005	Antiretroviral Pharmacology/Lactating Mother/Infants	1R21HD051470-01	1
2005	PERINATAL CORE PROTOCOL IN HIV INFECTED WOMEN (PACTG P1025, VERSION 20)	5M01RR000533-37-444	503
2005	ANTIRETROVIRAL DRUGS DURING PREGNANCY IN HIV POSITIVE FEMALES	5M01RR000533-37-5424	503

Showing 10 of 22 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Bekker A, Yang J, Wang J, Cotton MF, Cababasay M, Wiesner L, Moye J, Browning R, Nakwa FL, Rabie H, Violari A, Mirochnick M, Cressey TR, Capparelli EV. Safety and Pharmacokinetics of Lopinavir/Ritonavir Oral Solution in Preterm and Term Infants Starting Before 3 Months of Age. Pediatr Infect Dis J. 2024 Apr 01; 43(4):355-360. PMID: 38190642; PMCID: PMC10939833; DOI: 10.1097/INF.0000000000004243;

Persaud D, Bryson Y, Nelson BS, Tierney C, Cotton MF, Coletti A, Jao J, Spector SA, Mirochnick M, Capparelli EV, Costello D, Szewczyk J, Nicodimus N, Stranix-Chibanda L, Kekitiinwa AR, Korutaro V, Reding C, Carrington MN, Majji S, Yin DE, Jean-Philippe P, Chadwick EG. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1/2 proof-of-concept study. Lancet HIV. 2024 Jan; 11(1):e20-e30. PMID: 38061376

Momper JD, Nikanjam M, Best BM, Mirochnick M, Capparelli EV, Cressey TR. Brief Report: Dolutegravir Plasma Protein Binding and Unbound Concentrations During Pregnancy and Postpartum. J Acquir Immune Defic Syndr. 2023 Dec 01; 94(4):332-336. PMID: 37884053; PMCID: PMC10686188; DOI: 10.1097/QAI.0000000000003281;

Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron GB, Cotton MF, Eke AC, Cressey TR, Shapiro DE, Bacon K, Knowles K, George K, Browning R, Chakhtoura N, Rungruengthanakit K, Wiesner L, Capparelli EV, Stek AM, Mirochnick M, Best BM. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Antimicrob Agents Chemother. 2023 Nov 15; 67(11):e0073723. PMID: 37882552; PMCID: PMC10648924; DOI: 10.1128/aac.00737-23;

Brooks KM, Scarsi KK, Mirochnick M. Antiretrovirals for Human Immunodeficiency Virus Treatment and Prevention in Pregnancy. Obstet Gynecol Clin North Am. 2023 Mar; 50(1):205-218. PMID: 36822704

Eke AC, Mirochnick M, Lockman S. Antiretroviral Therapy and Adverse Pregnancy Outcomes in People Living with HIV. N Engl J Med. 2023 Jan 26; 388(4):344-356. PMID: 36720135; PMCID: PMC10400304; DOI: 10.1056/NEJMra2212877;

Liu XI, Dallmann A, Brooks K, Best BM, Clarke DF, Mirochnick M, van den Anker JN, Capparelli EV, Momper JD. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19. CPT Pharmacometrics Syst Pharmacol. 2023 Feb; 12(2):148-153.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 36479969; PMCID: PMC9877749; DOI: 10.1002/psp4.12900;

Coutinho CM, Warshaw MG, Duarte G, Stek A, Violari A, Hofer CB, Deville JG, Ngocho JS, Pilotto JH, Correa MD, Shapiro DE, Fuller TL, Chakhtoura N, Mirochnick M, João EC. Effects of Initiating Raltegravir-Based Versus Efavirenz-Based Antiretroviral Regimens During Pregnancy on Weight Changes and Perinatal Outcomes: NICHD P1081. J Acquir Immune Defic Syndr. 2022 Dec 01; 91(4):403-409. PMID: 36049477; PMCID: PMC9613542; DOI: 10.1097/QAI.0000000000003081;

Abrams EJ, Capparelli E, Ruel T, Mirochnick M. Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents. Clin Infect Dis. 2022 Nov 21; 75(Suppl 4):S562-S570. PMID: 36410381; PMCID: PMC10200315; DOI: 10.1093/cid/ciac754;

Béranger A, Bekker A, Solans BP, Cotton MF, Mirochnick M, Violari A, Wang J, Cababasay M, Wiesner L, Browning R, Moye J, Capparelli EV, Savic RM. Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. Clin Infect Dis. 2022 Sep 29; 75(6):1037-1045. PMID: 35134861; PMCID: PMC9522418; DOI: 10.1093/cid/ciac001;

Showing 10 of 159 results. Show More

Boyce CL, Beck IA, Styrchak SM, Hardy SR, Wallner JJ, Milne RS, Morrison RL, Shapiro DE, João EC, Mirochnick MH, Frenkel LM. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term. PLoS One. 2022; 17(9):e0275254. PMID: 36166463; PMCID: PMC9514603; DOI: 10.1371/journal.pone.0275254;

Liyanage M, Nikanjam M, McFadyen L, Vourvahis M, Rogg L, Moye J, Chadwick EG, Jean-Philippe P, Mirochnick M, Whitson K, Bradford S, Capparelli EV, Best BM. Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Pediatr Infect Dis J. 2022 Nov 01; 41(11):885-890. PMID: 35980827; PMCID: PMC9560968; DOI: 10.1097/INF.0000000000003665;

Brooks KM, Pinilla M, Stek AM, Shapiro DE, Barr E, Febo IL, Paul ME, Deville JG, George K, Knowles K, Rungruengthanakit K, Browning R, Chakhtoura N, Capparelli EV, Mirochnick M, Best BM. Pharmacokinetics of Tenofovir Alafenamide With Boosted Protease Inhibitors in Pregnant and Postpartum Women Living With HIV: Results From IMPAACT P1026s. J Acquir Immune Defic Syndr. 2022 07 01; 90(3):343-350. PMID: 35195573; PMCID: PMC9203910; DOI: 10.1097/QAI.0000000000002944;

Momper JD, Wang J, Stek A, Shapiro DE, Powis KM, Paul ME, Badell ML, Browning R, Chakhtoura N, Denson K, Rungruengthanakit K, George K, Capparelli EV, Mirochnick M, Best BM. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV. J Acquir Immune Defic Syndr. 2022 03 01; 89(3):303-309. PMID: 34732682; PMCID: PMC8837686; DOI: 10.1097/QAI.0000000000002856;

Piscitelli J, Nikanjam M, Best BM, Acosta E, Mirochnick M, Clarke DF, Capparelli EV, Momper JD. Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation. J Acquir Immune Defic Syndr. 2022 01 01; 89(1):108-114.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 34629412; PMCID: PMC8665018; DOI: 10.1097/QAI.0000000000002830;

Bekker A, Capparelli EV, Violari A, Cotton MF, Cababasay M, Wang J, Mathiba R, Wiesner L, Wiznia A, Samson P, Browning R, Moye J, Nakwa FL, Decloedt E, Rabie H, Mirochnick M, Cressey TR. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Lancet HIV. 2022 01; 9(1):e24-e31. PMID: 34883066; PMCID: PMC8760861; DOI: 10.1016/S2352-3018(21)00266-6;

Frenkel LM, Morrison RL, Fuller TL, Gouvêa MI, Benamor Teixeira ML, Coombs RW, Shapiro DE, Mirochnick M, Hennessey R, Whitson K, Chakhtoura N, João EC. Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2021 12 01; 88(4):361-365. PMID: 34369908; PMCID: PMC8547747; DOI: 10.1097/QAI.0000000000002771;

Denti P, Wasmann RE, Francis J, McIlleron H, Sugandhi N, Cressey TR, Mirochnick M, Capparelli EV, Penazzato M. One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. Lancet Child Adolesc Health. 2022 01; 6(1):9-10. PMID: 34678142

Zhao S, Gockenbach M, Grimstein M, Sachs HC, Mirochnick M, Struble K, Belew Y, Wang J, Capparelli EV, Best BM, Johnson T, Momper JD, Maharaj AR. Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development. Front Pediatr. 2021; 9:721059. PMID: 34722417; PMCID: PMC8550258; DOI: 10.3389/fped.2021.721059;

Kreitchmann R, Stek A, Best BM, Capparelli E, Wang J, Shapiro D, Chakhtoura N, Mirochnick M, Eke AC. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens. Contraception. 2022 01; 105:67-74. PMID: 34407424; PMCID: PMC8678338; DOI: 10.1016/j.contraception.2021.08.006;

Mulligan N, Salama E, Momper JD, Capparelli EV, Stek A, Chakhtoura N, Mirochnick M, Best BM. Lopinavir and tenofovir interaction observed in non-pregnant adults altered during pregnancy. J Clin Pharm Ther. 2021 Oct; 46(5):1459-1464. PMID: 34254323; PMCID: PMC8448937; DOI: 10.1111/jcpt.13477;

Momper JD, Wang J, Stek A, Shapiro DE, Scott GB, Paul ME, Febo IL, Burchett S, Smith E, Chakhtoura N, Denson K, Rungruengthanakit K, George K, Yang DZ, Capparelli EV, Mirochnick M, Best BM. Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV. AIDS. 2021 07 01; 35(8):1191-1199. PMID: 34076612; PMCID: PMC8173003; DOI: 10.1097/QAD.0000000000002857;

Abrams EJ, Mofenson LM, Pozniak A, Lockman S, Colbers A, Belew Y, Clayden P, Mirochnick M, Siberry GK, Ford N, Khoo S, Renaud F, Vitoria M, Venter WDF, Doherty M, Penazzato M. Enhanced and Timely Investigation of ARVs for Use in Pregnant Women. J Acquir Immune Defic Syndr. 2021 04 15; 86(5):607-615. PMID: 33298793

Rosebush JC, Best BM, Chadwick EG, Butler K, Moye J, Smith E, Bradford S, Reding CA, Mathiba SR, Hanley S, Aziz M, Homans J, Acosta EP, Murtaugh W, Vourvahis M, Mcfadyen L, Hayward K, Mirochnick M, Samson P. Pharmacokinetics and safety of maraviroc in neonates. AIDS. 2021 03 01; 35(3):419-427. PMID: 33252481; PMCID: PMC7856036; DOI: 10.1097/QAD.0000000000002762;

Brooks KM, Momper JD, Pinilla M, Stek AM, Barr E, Weinberg A, Deville JG, Febo IL, Cielo M, George K, Denson K, Rungruengthanakit K, Shapiro DE, Smith E, Chakhtoura N, Rooney JF, Haubrich R, Espina R, Capparelli EV, Mirochnick M, Best BM. Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. AIDS. 2021 03 01; 35(3):407-417. PMID: 33252495; PMCID: PMC8238253; DOI: 10.1097/QAD.0000000000002767;

Eke AC, Shoji K, Best BM, Momper JD, Stek AM, Cressey TR, Mirochnick M, Capparelli EV. Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. Antimicrob Agents Chemother. 2021 02 17; 65(3). PMID: 33318014; PMCID: PMC8092509; DOI: 10.1128/AAC.02168-20;

Liu XI, Momper JD, Rakhmanina NY, Green DJ, Burckart GJ, Cressey TR, Mirochnick M, Best BM, van den Anker JN, Dallmann A. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. Clin Pharmacokinet. 2021 06; 60(6):795-809. PMID: 33527213; PMCID: PMC9334904; DOI: 10.1007/s40262-020-00977-w;

Clarke DF, Lommerse J, Acosta EP, Cababasay MP, Wang J, Spector SA, Chain A, Smith E, Teppler H, Hazra R, Calabrese K, Graham B, Popson S, Bryson Y, Mirochnick M. Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097. J Acquir Immune Defic Syndr. 2020 12 15; 85(5):626-634.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 32925360; PMCID: PMC8043209; DOI: 10.1097/QAI.0000000000002492;

Ruel TD, Capparelli EV, Tierney C, Nelson BS, Coletti A, Bryson Y, Cotton MF, Spector SA, Mirochnick M, LeBlanc R, Reding C, Zimmer B, Persaud D, Bwakura-Dangarembizi M, Naidoo KL, Hazra R, Jean-Philippe P, Chadwick EG. Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Lancet HIV. 2021 03; 8(3):e149-e157. PMID: 33242457; PMCID: PMC7933083; DOI: 10.1016/S2352-3018(20)30274-5;

Liu XI, Momper JD, Rakhmanina NY, Green DJ, Burckart GJ, Cressey TR, Mirochnick M, Best BM, van den Anker JN, Dallmann A. Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling. Clin Pharmacokinet. 2020 11; 59(11):1433-1450. PMID: 32451908; PMCID: PMC7666002; DOI: 10.1007/s40262-020-00897-9;

Eke AC, Olagunju A, Momper J, Penazzato M, Abrams EJ, Best BM, Capparelli EV, Bekker A, Belew Y, Kiser JJ, Struble K, Taylor G, Waitt C, Mirochnick M, Cressey TR, Colbers A. Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. Clin Pharmacol Ther. 2021 07; 110(1):36-48. PMID: 32930408; PMCID: PMC8167886; DOI: 10.1002/cpt.2048;

Eke AC, Olagunju A, Best BM, Mirochnick M, Momper JD, Abrams E, Penazzato M, Cressey TR, Colbers A. Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV. Clin Pharmacokinet. 2020 10; 59(10):1185-1194. PMID: 32757103; PMCID: PMC7550310; DOI: 10.1007/s40262-020-00915-w;

Bustinduy AL, Kolamunnage-Dona R, Mirochnick MH, Capparelli EV, Tallo V, Acosta LP, Olveda RM, Friedman JF, Hope WW. Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum. Antimicrob Agents Chemother. 2020 08 20; 64(9). PMID: 32631820; PMCID: PMC7449211; DOI: 10.1128/AAC.00566-20;

Salama E, Eke AC, Best BM, Mirochnick M, Momper JD. Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy. J Clin Pharmacol. 2020 12; 60(12):1537-1550. PMID: 32798276; PMCID: PMC8227837; DOI: 10.1002/jcph.1714;

Clarke DF, Acosta EP, Cababasay M, Wang J, Chain A, Teppler H, Popson S, Graham B, Smith B, Hazra R, Calabrese K, Bryson Y, Spector SA, Lommerse J, Mirochnick M. Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020 05 01; 84(1):70-77.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 31913995; PMCID: PMC7144886; DOI: 10.1097/QAI.0000000000002294;

João EC, Morrison RL, Shapiro DE, Chakhtoura N, Gouvèa MIS, de Lourdes B Teixeira M, Fuller TL, Mmbaga BT, Ngocho JS, Njau BN, Violari A, Mathiba R, Essack Z, Pilotto JHS, Moreira LF, Rolon MJ, Cahn P, Prommas S, Cressey TR, Chokephaibulkit K, Werarak P, Laimon L, Hennessy R, Frenkel LM, Anthony P, Best BM, Siberry GK, Mirochnick M. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. Lancet HIV. 2020 05; 7(5):e322-e331. PMID: 32386720; PMCID: PMC7323582; DOI: 10.1016/S2352-3018(20)30038-2;

Eke AC, Stek AM, Wang J, Kreitchmann R, Shapiro DE, Smith E, Chakhtoura N, Capparelli EV, Mirochnick M, Best BM. Darunavir Pharmacokinetics With an Increased Dose During Pregnancy. J Acquir Immune Defic Syndr. 2020 04 01; 83(4):373-380. PMID: 31923087; PMCID: PMC7258985; DOI: 10.1097/QAI.0000000000002261;

Eke AC, Wang J, Amin K, Shapiro DE, Stek A, Smith E, Chakhtoura N, Basar M, George K, Knapp KM, João EC, Rungruengthanakit K, Capparelli E, Burchett S, Mirochnick M, Best BM. Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. Antimicrob Agents Chemother. 2020 03 24; 64(4). PMID: 32015036; PMCID: PMC7179299; DOI: 10.1128/AAC.02260-19;

Eke AC, Brooks KM, Gebreyohannes RD, Sheffield JS, Dooley KE, Mirochnick M. Tenofovir alafenamide use in pregnant and lactating women living with HIV. Expert Opin Drug Metab Toxicol. 2020 Apr; 16(4):333-342. PMID: 32125906; PMCID: PMC9214649; DOI: 10.1080/17425255.2020.1738384;

Bunglawala F, Rajoli RKR, Mirochnick M, Owen A, Siccardi M. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. J Antimicrob Chemother. 2020 03 01; 75(3):640-647. PMID: 31860112

Aizire J, Brooks KM, Mirochnick M, Flynn PM, Butler K, Kiser JJ, Siberry GK, Fenton T, Cababasay M, Fowler MG. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. J Acquir Immune Defic Syndr. 2020 02 01; 83(2):173-180. PMID: 31929405; PMCID: PMC7409985; DOI: 10.1097/QAI.0000000000002247;

Clarke DF, Mirochnick M, Acosta EP, Capparelli E, Chain A, Teppler H, Smith B, Lommerse J. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. J Acquir Immune Defic Syndr. 2019 12 01; 82(4):392-398.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 31658182; PMCID: PMC6820708; DOI: 10.1097/QAI.0000000000002149;

Colbers A, Mirochnick M, Schalkwijk S, Penazzato M, Townsend C, Burger D. Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus. Clin Infect Dis. 2019 09 13; 69(7):1254-1258. PMID: 30783649; PMCID: PMC6743813; DOI: 10.1093/cid/ciz121;

Liu XI, Momper JD, Rakhmanina N, van den Anker JN, Green DJ, Burckart GJ, Best BM, Mirochnick M, Capparelli EV, Dallmann A. Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir. J Clin Pharmacol. 2020 02; 60(2):240-255. PMID: 31489678; PMCID: PMC7316130; DOI: 10.1002/jcph.1515;

Levesque BM, Burnham L, Cardoza N, Adams M, Cohen R, Mirochnick M, Fujii A, Sinha B. Improving Respiratory Support Practices to Reduce Chronic Lung Disease in Premature Infants. Pediatr Qual Saf. 2019 Jul-Aug; 4(4):e193.View Related Profiles.

Fujii, Alan
Levesque, Bernadette
Sinha, Bharati
Mirochnick, Mark

PMID: 31572894; PMCID: PMC6708652; DOI: 10.1097/pq9.0000000000000193;

Nachman S, Townsend CL, Abrams EJ, Archary M, Capparelli E, Clayden P, Lockman S, Jean-Philippe P, Mayer K, Mirochnick M, McKenzie-White J, Struble K, Watts H, Flexner C. Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities. Lancet HIV. 2019 08; 6(8):e552-e558. PMID: 31307946; PMCID: PMC7152795; DOI: 10.1016/S2352-3018(19)30147-X;

Lommerse J, Clarke D, Kerbusch T, Merdjan H, Witjes H, Teppler H, Mirochnick M, Acosta EP, Wenning L, Nachman S, Chain A. Maternal-Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing. CPT Pharmacometrics Syst Pharmacol. 2019 09; 8(9):643-653. PMID: 31215170; PMCID: PMC6765695; DOI: 10.1002/psp4.12443;

Momper JD, Hanan NJ, Rossi SS, Mirochnick MH, Cafferata ML, Lavenia A, Flores I, Gibbons L, Ciganda A, Sosa Estani S, Capparelli EV, Buekens P. Determination of Benznidazole in Human Dried Blood Spots by Liquid Chromatography-Mass Spectrometry to Monitor Adherence to Trypanosoma cruzi Infection Treatment in Infants and Children. Am J Trop Med Hyg. 2019 07; 101(1):116-122. PMID: 31115303; PMCID: PMC6609196; DOI: 10.4269/ajtmh.18-0852;

Eke AC, Mirochnick M. Ritonavir and cobicistat as pharmacokinetic enhancers in pregnant women. Expert Opin Drug Metab Toxicol. 2019 Jul; 15(7):523-525. PMID: 31185758; PMCID: PMC9210948; DOI: 10.1080/17425255.2019.1628947;

Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. J Antimicrob Chemother. 2019 05 01; 74(5):1348-1356. PMID: 30715324; PMCID: PMC6477987; DOI: 10.1093/jac/dky567;

Eke AC, Mirochnick MH. Cobicistat as a Pharmacoenhancer in Pregnancy and Postpartum: Progress to Date and Next Steps. J Clin Pharmacol. 2019 06; 59(6):779-783. PMID: 30821843; PMCID: PMC9228990; DOI: 10.1002/jcph.1397;

Kreitchmann R, Schalkwijk S, Best B, Wang J, Colbers A, Stek A, Shapiro D, Cressey T, Mirochnick M, Burger D. Efavirenz pharmacokinetics during pregnancy and infant washout. Antivir Ther. 2019; 24(2):95-103. PMID: 30530925; PMCID: PMC6642905; DOI: 10.3851/IMP3283;

Momper JD, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Badell ML, Acosta EP, Purswani M, Smith E, Chakhtoura N, Park K, Burchett S, Shapiro DE, Mirochnick M. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018 11 13; 32(17):2507-2516. PMID: 30134297; PMCID: PMC6209536; DOI: 10.1097/QAD.0000000000001992;

Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clin Pharmacokinet. 2018 11; 57(11):1421-1433. PMID: 29520730; PMCID: PMC6182466; DOI: 10.1007/s40262-018-0642-9;

Eke AC, McCormack SA, Best BM, Stek AM, Wang J, Kreitchmann R, Shapiro D, Smith E, Mofenson LM, Capparelli EV, Mirochnick M. Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum. J Clin Pharmacol. 2019 03; 59(3):386-393. PMID: 30358179; PMCID: PMC6368469; DOI: 10.1002/jcph.1331;

Adachi K, Xu J, Ank B, Watts DH, Camarca M, Mofenson LM, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Machado DM, Ceriotto M, Morgado MG, Bryson YJ, Veloso VG, Grinsztejn B, Mirochnick M, Moye J, Nielsen-Saines K. Congenital Cytomegalovirus and HIV Perinatal Transmission. Pediatr Infect Dis J. 2018 10; 37(10):1016-1021. PMID: 30216294; PMCID: PMC6129438; DOI: 10.1097/INF.0000000000001975;

Schreiner CN, Ahlfors CE, Wong RJ, Stevenson DK, Clarke DF, Mirochnick M. In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding. Pediatr Infect Dis J. 2018 09; 37(9):908-909.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 29561509

Eke AC, Chakhtoura N, Kashuba A, Best BM, Sykes C, Wang J, Stek AM, Smith E, Calabrese S, Capparelli EV, Mirochnick M. Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. J Acquir Immune Defic Syndr. 2018 07 01; 78(3):308-313. PMID: 29528944; PMCID: PMC6002878; DOI: 10.1097/QAI.0000000000001677;

Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E, Chakhtoura N, Burchett S, Mirochnick M. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018 03 27; 32(6):729-737. PMID: 29369162; PMCID: PMC5854536; DOI: 10.1097/QAD.0000000000001755;

Adachi K, Xu J, Ank B, Watts DH, Camarca M, Mofenson LM, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Machado DM, Ceriotto M, Morgado MG, Bryson YJ, Veloso VG, Grinsztejn B, Mirochnick M, Moye J, Nielsen-Saines K. Congenital CMV and HIV Perinatal Transmission. Pediatr Infect Dis J. 2018 Mar 09. PMID: 29528912

Pinto JA, Capparelli EV, Warshaw M, Zimmer B, Cressey TR, Spector SA, Qin M, Smith B, Siberry GK, Mirochnick M. A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. Pediatr Infect Dis J. 2018 02; 37(2):e29-e35. PMID: 29088027; PMCID: PMC5762400; DOI: 10.1097/INF.0000000000001817;

Adachi K, Xu J, Yeganeh N, Camarca M, Morgado MG, Watts DH, Mofenson LM, Veloso VG, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado DM, Bryson YJ, Grinsztejn B, Moye J, Klausner JD, Bristow CC, Dickover R, Mirochnick M, Nielsen-Saines K. Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission. PLoS One. 2018; 13(1):e0189851. PMID: 29304083; PMCID: PMC5755782; DOI: 10.1371/journal.pone.0189851;

Friedman JF, Olveda RM, Mirochnick MH, Bustinduy AL, Elliott AM. Praziquantel for the treatment of schistosomiasis during human pregnancy. Bull World Health Organ. 2018 Jan 01; 96(1):59-65. PMID: 29403101; PMCID: PMC5791873; DOI: 10.2471/BLT.17.198879;

Clarke DF, Penazzato M, Capparelli E, Cressey TR, Siberry G, Sugandhi N, Mirochnick M. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol. 2018 Jan; 11(1):83-93.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 29039686

Rimawi BH, Johnson E, Rajakumar A, Tao S, Jiang Y, Gillespie S, Schinazi RF, Mirochnick M, Badell ML, Chakraborty R. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy. Antimicrob Agents Chemother. 2017 Jun; 61(6). PMID: 28348149; PMCID: PMC5444129; DOI: 10.1128/AAC.02213-16;

Osorio LE, Boechat MI, Mirochnick M, Kumwenda N, Kreitchmann R, Emel L, Pinto J, Joao E, Santos B, Swenson M, George K, Sato P, Mofenson L, Nielsen-Saines K. Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. Pediatr Infect Dis J. 2017 Feb; 36(2):184-188. PMID: 27798550; PMCID: PMC5233548; DOI: 10.1097/INF.0000000000001386;

Mulligan N, Schalkwijk S, Best BM, Colbers A, Wang J, Capparelli EV, Moltó J, Stek AM, Taylor G, Smith E, Hidalgo Tenorio C, Chakhtoura N, van Kasteren M, Fletcher CV, Mirochnick M, Burger D. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women. Front Pharmacol. 2016; 7:239. PMID: 27540363; PMCID: PMC4972814; DOI: 10.3389/fphar.2016.00239;

Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N, Smith E, Shapiro DE, Mirochnick M. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. J Acquir Immune Defic Syndr. 2016 Jul 01; 72(3):289-96. PMID: 26918544; PMCID: PMC4911231; DOI: 10.1097/QAI.0000000000000968;

Gupta A, Mathad JS, Abdel-Rahman SM, Albano JD, Botgros R, Brown V, Browning RS, Dawson L, Dooley KE, Gnanashanmugam D, Grinsztejn B, Hernandez-Diaz S, Jean-Philippe P, Kim P, Lyerly AD, Mirochnick M, Mofenson LM, Montepiedra G, Piper J, Sahin L, Savic R, Smith B, Spiegel H, Swaminathan S, Watts DH, White A. Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. Clin Infect Dis. 2016 Mar 15; 62(6):761-9.View Related Profiles.

Mirochnick, Mark
Hernandez-Diaz, Sonia

PMID: 26658057; PMCID: PMC4772846; DOI: 10.1093/cid/civ991;

Cotton MF, Holgate S, Nelson A, Rabie H, Wedderburn C, Mirochnick M. The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. J Int AIDS Soc. 2015; 18(Suppl 6):20271. PMID: 26639118; PMCID: PMC4670832; DOI: 10.7448/IAS.18.7.20271;

Stek A, Best BM, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, Cressey TR, Mofenson LM, Smith E, Shapiro D, Mirochnick M. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. J Acquir Immune Defic Syndr. 2015 Sep 1; 70(1):33-41. PMID: 25950206; PMCID: PMC4579345; DOI: 10.1097/QAI.0000000000000668;

Colbers A, Best B, Schalkwijk S, Wang J, Stek A, Hidalgo Tenorio C, Hawkins D, Taylor G, Kreitchmann R, Burchett S, Haberl A, Kabeya K, van Kasteren M, Smith E, Capparelli E, Burger D, Mirochnick M. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clin Infect Dis. 2015 Nov 15; 61(10):1582-9. PMID: 26202768; PMCID: PMC4614410; DOI: 10.1093/cid/civ587;

Best BM, Burchett S, Li H, Stek A, Hu C, Wang J, Hawkins E, Byroads M, Watts DH, Smith E, Fletcher CV, Capparelli EV, Mirochnick M. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sep; 16(8):502-11. PMID: 25959631; PMCID: PMC4862736; DOI: 10.1111/hiv.12252;

Sheffield JS, Siegel D, Mirochnick M, Heine RP, Nguyen C, Bergman KL, Savic RM, Long J, Dooley KE, Nesin M. Designing drug trials: considerations for pregnant women. Clin Infect Dis. 2014 Dec 15; 59 Suppl 7:S437-44. PMID: 25425722; PMCID: PMC4303056; DOI: 10.1093/cid/ciu709;

Watts DH, Stek A, Best BM, Wang J, Capparelli EV, Cressey TR, Aweeka F, Lizak P, Kreitchmann R, Burchett SK, Shapiro DE, Hawkins E, Smith E, Mirochnick M. Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014 Dec 1; 67(4):375-81. PMID: 25162818; PMCID: PMC4213295; DOI: 10.1097/QAI.0000000000000318;

Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M, Capparelli EV. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med. 2015 Mar; 16(3):176-83. PMID: 25407158; PMCID: PMC4320673; DOI: 10.1111/hiv.12195;

Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr. 2014 Nov 1; 67(3):310-5.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 25162819; PMCID: PMC4197108; DOI: 10.1097/QAI.0000000000000316;

Cressey TR, Urien S, Capparelli EV, Best BM, Buranabanjasatean S, Limtrakul A, Rawangban B, Sabsanong P, Treluyer JM, Jourdain G, Stek A, Lallemant M, Mirochnick M. Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy. J Antimicrob Chemother. 2015 Jan; 70(1):217-24. PMID: 25261418; PMCID: PMC4267507; DOI: 10.1093/jac/dku367;

Gill CJ, MacLeod WB, Phiri-Mazala G, Guerina NG, Mirochnick M, Knapp AB, Hamer DH. Can traditional birth attendants be trained to accurately identify septic infants, initiate antibiotics, and refer in a rural African setting? Glob Health Sci Pract. 2014 Aug; 2(3):318-27.View Related Profiles.

Gill, Christopher
Hamer, Davidson
Mirochnick, Mark
MacLeod, William

PMID: 25276591; PMCID: PMC4168634; DOI: 10.9745/GHSP-D-14-00045;

Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, Pinto J, Santos B, Parsons T, Kearney B, Emel L, Herron C, Richardson P, Hudelson SE, Eshleman SH, George K, Fowler MG, Sato P, Mofenson L. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014 Jan 1; 65(1):33-41. PMID: 23979002; PMCID: PMC3912736; DOI: 10.1097/QAI.0b013e3182a921eb;

Cressey TR, Best BM, Achalapong J, Stek A, Wang J, Chotivanich N, Yuthavisuthi P, Suriyachai P, Prommas S, Shapiro DE, Watts DH, Smith E, Capparelli E, Kreitchmann R, Mirochnick M. Reduced indinavir exposure during pregnancy. Br J Clin Pharmacol. 2013 Sep; 76(3):475-83. PMID: 23305215; PMCID: PMC3769674; DOI: 10.1111/bcp.12078;

Clarke DF, Wong RJ, Wenning L, Stevenson DK, Mirochnick M. Raltegravir in vitro effect on bilirubin binding. Pediatr Infect Dis J. 2013 Sep; 32(9):978-80.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 23470680; PMCID: PMC3856729; DOI: 10.1097/INF.0b013e31829044a8;

Kreitchmann R, Best BM, Wang J, Stek A, Caparelli E, Watts DH, Smith E, Shapiro DE, Rossi S, Burchett SK, Hawkins E, Byroads M, Cressey TR, Mirochnick M. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy. J Acquir Immune Defic Syndr. 2013 May 1; 63(1):59-66. PMID: 23392467; PMCID: PMC3625451; DOI: 10.1097/QAI.0b013e318289b4d2;

Fogel JM, Mwatha A, Richardson P, Brown ER, Chipato T, Alexandre M, Moodley D, Elbireer A, Mirochnick M, George K, Mofenson LM, Zwerski S, Coovadia HM, Eshleman SH. Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J. 2013 Apr; 32(4):e164-9. PMID: 23249916; PMCID: PMC3826537; DOI: 10.1097/INF.0b013e31827f44ee;

Krekels EH, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, Mirochnick M, Knibbe CA. From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to Zidovudine. CPT Pharmacometrics Syst Pharmacol. 2012; 1:e9. PMID: 23887364; PMCID: PMC3603431; DOI: 10.1038/psp.2012.11;

Fogel JM, Taha TE, Sun J, Hoover DR, Parsons TL, Kumwenda JJ, Mofenson LM, Fowler MG, Hendrix CW, Kumwenda NI, Eshleman SH, Mirochnick M. Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants. J Acquir Immune Defic Syndr. 2012 Aug 15; 60(5):462-5. PMID: 22614899; PMCID: PMC3404155; DOI: 10.1097/QAI.0b013e31825ddcfa;

Nielsen-Saines K, Watts DH, Veloso VG, Bryson YJ, Joao EC, Pilotto JH, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado D, Bethel J, Morgado MG, Dickover R, Camarca M, Mirochnick M, Siberry G, Grinsztejn B, Moreira RI, Bastos FI, Xu J, Moye J, Mofenson LM. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012 Jun 21; 366(25):2368-79. PMID: 22716975; PMCID: PMC3590113; DOI: 10.1056/NEJMoa1108275;

Cressey TR, Stek A, Capparelli E, Bowonwatanuwong C, Prommas S, Sirivatanapa P, Yuthavisuthi P, Neungton C, Huo Y, Smith E, Best BM, Mirochnick M. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr. 2012 Mar 1; 59(3):245-52. PMID: 22083071; PMCID: PMC3288559; DOI: 10.1097/QAI.0b013e31823ff052;

Sinha B, Mirochnick MH, Kumar S, Fujii AM. Targeted echocardiography in the neonatal intensive care unit. J Am Soc Echocardiogr. 2012 Mar; 25(3):361; author reply 361-2.View Related Profiles.

Fujii, Alan
Sinha, Bharati
Mirochnick, Mark

PMID: 22297083; DOI: 10.1016/j.echo.2012.01.001;

Tremoulet AH, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV. Developmental pharmacokinetic changes of Lamivudine in infants and children. J Clin Pharmacol. 2012 Dec; 52(12):1824-32. PMID: 22180560; PMCID: PMC3369109; DOI: 10.1177/0091270011426563;

Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, Frenkel L, Britto P, Roongpisuthipong A, Beck IA, Yuthavisuthi P, Prommas S, Puthanakit T, Achalapong J, Chotivanich N, Rasri W, Cressey TR, Maupin R, Mirochnick M, Jourdain G. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. Clin Infect Dis. 2012 Jan 15; 54(2):285-93. PMID: 22144539; PMCID: PMC3245730; DOI: 10.1093/cid/cir798;

Stek AM, Best BM, Luo W, Capparelli E, Burchett S, Hu C, Li H, Read JS, Jennings A, Barr E, Smith E, Rossi SS, Mirochnick M. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 2012 Apr; 13(4):226-35. PMID: 22129166; PMCID: PMC3342997; DOI: 10.1111/j.1468-1293.2011.00965.x;

Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E, Cotter A, Purswani M. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother. 2011 Dec; 55(12):5914-22. PMID: 21896911; PMCID: PMC3232794; DOI: 10.1128/AAC.00544-11;

Mugabo P, Els I, Smith J, Rabie H, Smith P, Mirochnick M, Steyn W, Hall D, Madsen R, Cotton MF. Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. S Afr Med J. 2011 Sep; 101(9):655-8. PMID: 21920159

Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Veloso VG, Rossi S, Moye J, Bryson Y, Mofenson L, Camarca M, Watts DH. Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life. Pediatr Infect Dis J. 2011 Sep; 30(9):769-72. PMID: 21666540; PMCID: PMC3158246; DOI: 10.1097/INF.0b013e3182242950;

Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr. 2011 Apr 15; 56(5):412-9. PMID: 21283017; PMCID: PMC3125419; DOI: 10.1097/QAI.0b013e31820fd093;

Mirochnick M, Clarke D. Oseltamivir pharmacokinetics in pregnancy: a commentary. Am J Obstet Gynecol. 2011 Jun; 204(6 Suppl 1):S94-5.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 21640232; DOI: 10.1016/j.ajog.2011.02.043;

Gill CJ, Phiri-Mazala G, Guerina NG, Kasimba J, Mulenga C, MacLeod WB, Waitolo N, Knapp AB, Mirochnick M, Mazimba A, Fox MP, Sabin L, Seidenberg P, Simon JL, Hamer DH. Effect of training traditional birth attendants on neonatal mortality (Lufwanyama Neonatal Survival Project): randomised controlled study. BMJ. 2011; 342:d346.View Related Profiles.

Gill, Christopher
Hamer, Davidson
Simon, Jonathon
Sabin, Lora
Mirochnick, Mark
Fox, Matthew
Seidenberg, Phil
MacLeod, William

PMID: 21292711; PMCID: PMC3032994; DOI: 10.1136/bmj.d346;

Mirochnick M, Best BM, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol. 2010 Dec; 37(4):907-27, xi.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 21078458; DOI: 10.1016/j.clp.2010.08.006;

Best BM, Stek AM, Mirochnick M, Hu C, Li H, Burchett SK, Rossi SS, Smith E, Read JS, Capparelli EV. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010 Aug; 54(4):381-8. PMID: 20632458; PMCID: PMC3265163

Brogly SB, Foca M, Deville JG, Mirochnick M, Scott GB, Mofenson LM, Read JS, Viani RM, Burchett SK, Cooper ER, Browning R, Shapiro DE. Potential confounding of the association between exposure to nucleoside analogues and mitochondrial dysfunction in HIV-uninfected and indeterminate infants. J Acquir Immune Defic Syndr. 2010 Jan; 53(1):154-7.View Related Profiles.

Cooper, Ellen
Mirochnick, Mark
Brogly, Susan

PMID: 20035168; PMCID: PMC3241607; DOI: 10.1097/QAI.0b013e3181b3adc2;

Aweeka FT, Stek A, Best BM, Hu C, Holland D, Hermes A, Burchett SK, Read J, Mirochnick M, Capparelli EV. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med. 2010 Apr; 11(4):232-8. PMID: 20002783; PMCID: PMC2874627; DOI: 10.1111/j.1468-1293.2009.00767.x;

Cressey TR, Van Dyke R, Jourdain G, Puthanakit T, Roongpisuthipong A, Achalapong J, Yuthavisuthi P, Prommas S, Chotivanich N, Maupin R, Smith E, Shapiro DE, Mirochnick M. Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women. Antimicrob Agents Chemother. 2009 May; 53(5):2189-91. PMID: 19237646; PMCID: PMC2681511; DOI: 10.1128/AAC.01091-08;

Bennetto-Hood C, Bryson YJ, Stek A, King JR, Mirochnick M, Acosta EP. Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum. HIV Clin Trials. 2009 Jan-Feb; 10(1):41-7. PMID: 19362995; DOI: 10.1310/hct1001-041;

Mirochnick M, Thomas T, Capparelli E, Zeh C, Holland D, Masaba R, Odhiambo P, Fowler MG, Weidle PJ, Thigpen MC. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009 Mar; 53(3):1170-6. PMID: 19114673; PMCID: PMC2650559; DOI: 10.1128/AAC.01117-08;

Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):485-91. PMID: 18989231; PMCID: PMC3912695; DOI: 10.1097/QAI.0b013e318186edd0;

Read JS, Best BM, Stek AM, Hu C, Capparelli EV, Holland DT, Burchett SK, Smith ME, Sheeran EC, Shearer WT, Febo I, Mirochnick M. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008 Nov; 9(10):875-82. PMID: 18795962; PMCID: PMC2732353; DOI: 10.1111/j.1468-1293.2008.00640.x;

Capparelli EV, Aweeka F, Hitti J, Stek A, Hu C, Burchett SK, Best B, Smith E, Read JS, Watts H, Nachman S, Thorpe EM, Spector SA, Jimenez E, Shearer WT, Foca M, Mirochnick M. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 2008 Apr; 9(4):214-20. PMID: 18366444; PMCID: PMC2755564; DOI: 10.1111/j.1468-1293.2008.00553.x;

Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Jiménez E, Veloso VG, Parsons T, Watts DH, Moye J, Mofenson LM, Camarca M, Bryson Y. Nevirapine concentrations in newborns receiving an extended prophylactic regimen. J Acquir Immune Defic Syndr. 2008 Mar 1; 47(3):334-7. PMID: 18398973

Bryson YJ, Mirochnick M, Stek A, Mofenson LM, Connor J, Capparelli E, Watts DH, Huang S, Hughes MD, Kaiser K, Purdue L, Asfaw Y, Keller M, Smith E. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials. 2008 Mar-Apr; 9(2):115-25. PMID: 18474496; PMCID: PMC4043374; DOI: 10.1310/hct0902-115;

Mirochnick M, Rodman JH, Robbins BL, Fridland A, Gandía J, Hitti J, Bardeguez A, Rathore MH, Gonzalez Garcia A, Cababasay M, Samson P, Mofenson L, Bryson YJ, Dorenbaum A. Pharmacokinetics of oral zidovudine administered during labour: a preliminary study. HIV Med. 2007 Oct; 8(7):451-6. PMID: 17760737

Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother. 2007 Dec; 51(12):4297-302. PMID: 17893155; PMCID: PMC2168008; DOI: 10.1128/AAC.00332-07;

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS. Reduced lopinavir exposure during pregnancy. AIDS. 2006 Oct 3; 20(15):1931-9. PMID: 16988514

Best BM, Mirochnick M, Capparelli EV, Stek A, Burchett SK, Holland DT, Read JS, Smith E, Hu C, Spector SA, Connor JD. Impact of pregnancy on abacavir pharmacokinetics. AIDS. 2006 Feb 28; 20(4):553-60. PMID: 16470119

Jackson JB, Parsons T, Musoke P, Nakabiito C, Donnell D, Fleming T, Mirochnick M, Mofenson L, Fowler MG, Mmiro F, Guay L. Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. AIDS. 2006 Jan 9; 20(2):217-22. PMID: 16511414

Shapiro RL, Holland DT, Capparelli E, Lockman S, Thior I, Wester C, Stevens L, Peter T, Essex M, Connor JD, Mirochnick M. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis. 2005 Sep 1; 192(5):720-7. PMID: 16088821

Mirochnick M, Stek A, Acevedo M, Keller M, Holland D, Capparelli E, Connor J, Huang S, Hughes M, Watts H, Mofenson L, Bryson Y. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. J Acquir Immune Defic Syndr. 2005 Jun 1; 39(2):189-94. PMID: 15905735

Cressey TR, Jourdain G, Lallemant MJ, Kunkeaw S, Jackson JB, Musoke P, Capparelli E, Mirochnick M. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005 Mar 1; 38(3):283-8. PMID: 15735445

Capparelli E, Rakhmanina N, Mirochnick M. Pharmacotherapy of perinatal HIV. Semin Fetal Neonatal Med. 2005 Apr; 10(2):161-75. PMID: 15701581

Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet. 2004; 43(15):1071-87. PMID: 15568888

Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Mwatha A, Emel L, Duefield C, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003 Sep 13; 362(9387):859-68. PMID: 13678973

Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, Culnane M, Sullivan JL. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003 Jun 1; 33(2):153-6. PMID: 12794547

Capparelli EV, Mirochnick M, Dankner WM, Blanchard S, Mofenson L, McSherry GD, Gay H, Ciupak G, Smith B, Connor JD. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr. 2003 Jan; 142(1):47-52. PMID: 12520254

Fujii AM, Brown E, Mirochnick M, O'Brien S, Kaufman G. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol. 2002 Oct-Nov; 22(7):535-40.View Related Profiles.

Fujii, Alan
Mirochnick, Mark
O'Brien, Sharon

PMID: 12368968

Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J. 2002 Sep; 21(9):835-8. PMID: 12352805

Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002 Jul 10; 288(2):189-98. PMID: 12095383

Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001 Oct 19; 15(15):1951-7. PMID: 11600822

Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J. 2001 Aug; 20(8):803-5. PMID: 11734746

Mirochnick M, Cooper E, Capparelli E, McIntosh K, Lindsey J, Xu J, Jacobus D, Mofenson L, Bonagura VR, Nachman S, Yogev R, Sullivan JL, Spector SA. Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection. Clin Pharmacol Ther. 2001 Jul; 70(1):24-32.View Related Profiles.

Cooper, Ellen
Mirochnick, Mark

PMID: 11452241

Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci. 2000 Nov; 918:287-97. PMID: 11131716

Mirochnick M, Clarke DF, McNamara ER, Cabral H. Bioequivalence of a propylene glycol-based liquid dapsone preparation and dapsone tablets. Am J Health Syst Pharm. 2000 Oct 1; 57(19):1775-7.View Related Profiles.

Clarke, Diana
Cabral, Howard
Mirochnick, Mark

PMID: 11030029

Mirochnick M, Clarke DF, Dorenbaum A. Nevirapine: pharmacokinetic considerations in children and pregnant women. Clin Pharmacokinet. 2000 Oct; 39(4):281-93.View Related Profiles.

Clarke, Diana
Mirochnick, Mark

PMID: 11069214

Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, Mofenson LM, Mirochnick M, Mmiro F, Eshleman SH. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000 Jul 28; 14(11):F111-5. PMID: 10983633

Frank DA, McCarten KM, Robson CD, Mirochnick M, Cabral H, Park H, Zuckerman B. Level of in utero cocaine exposure and neonatal ultrasound findings. Pediatrics. 1999 Nov; 104(5 Pt 1):1101-5.View Related Profiles.

Zuckerman, Barry
Frank, Deborah
Cabral, Howard
Mirochnick, Mark

PMID: 10545554; PMCID: PMC2365465

Mirochnick M, Cooper E, McIntosh K, Xu J, Lindsey J, Jacobus D, Mofenson L, Sullivan JL, Dankner W, Frenkel LM, Nachman S, Wara DW, Johnson D, Bonagura VR, Rathore MH, Cunningham CK, McNamara J. Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 1999 Nov; 43(11):2586-91.View Related Profiles.

Cooper, Ellen
Mirochnick, Mark

PMID: 10543733; PMCID: PMC89529

Vinci RJ, Fish S, Mirochnick M. Cocaine absorption after application of a viscous cocaine-containing TAC solution. Ann Emerg Med. 1999 Oct; 34(4 Pt 1):498-502.View Related Profiles.

Mirochnick, Mark
Vinci, Robert
Fish, Susan

PMID: 10499951

Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999 Sep 4; 354(9181):795-802. PMID: 10485720

Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Ther. 1999 Jul; 66(1):16-24. PMID: 10430105

McIntosh K, Cooper E, Xu J, Mirochnick M, Lindsey J, Jacobus D, Mofenson L, Yogev R, Spector SA, Sullivan JL, Sacks H, Kovacs A, Nachman S, Sleasman J, Bonagura V, McNamara J. Toxicity and efficacy of daily vs. weekly dapsone for prevention of Pneumocystis carinii pneumonia in children infected with human immunodeficiency virus. ACTG 179 Study Team. AIDS Clinical Trials Group. Pediatr Infect Dis J. 1999 May; 18(5):432-9.View Related Profiles.

Cooper, Ellen
Mirochnick, Mark

PMID: 10353516

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, Elliott T, Horton S, Dransfield K, Pav JW, Murarka A, Allen M, Fowler MG, Mofenson L, Hom D, Mmiro F, Jackson JB. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999 Mar 11; 13(4):479-86. PMID: 10197376

Needlman R, Frank DA, Cabral H, Mirochnick M, Kwon C, Zuckerman B. Blood pressure in children exposed prenatally to cocaine. Clin Pediatr (Phila). 1998 Nov; 37(11):659-64.View Related Profiles.

Zuckerman, Barry
Frank, Deborah
Cabral, Howard
Mirochnick, Mark

PMID: 9825209

Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998 Aug; 178(2):368-74. PMID: 9697716

Mirochnick M, Capparelli E, Dankner W, Sperling RS, van Dyke R, Spector SA. Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus. Antimicrob Agents Chemother. 1998 Apr; 42(4):808-12. PMID: 9559787; PMCID: PMC105546

Mirochnick M, Meyer J, Frank DA, Cabral H, Tronick EZ, Zuckerman B. Elevated plasma norepinephrine after in utero exposure to cocaine and marijuana. Pediatrics. 1997 Apr; 99(4):555-9.View Related Profiles.

Zuckerman, Barry
Frank, Deborah
Cabral, Howard
Mirochnick, Mark

PMID: 9093298; PMCID: PMC2365460

Tronick EZ, Frank DA, Cabral H, Mirochnick M, Zuckerman B. Late dose-response effects of prenatal cocaine exposure on newborn neurobehavioral performance. Pediatrics. 1996 Jul; 98(1):76-83.View Related Profiles.

Zuckerman, Barry
Frank, Deborah
Cabral, Howard
Mirochnick, Mark

PMID: 8668416; PMCID: PMC2373273

Rich JD, Mirochnick M. Dapsone penetrates cerebrospinal fluid during Pneumocystis carinii pneumonia prophylaxis. Diagn Microbiol Infect Dis. 1996 Feb; 24(2):77-9. PMID: 9147912

Mirochnick M, Frank DA, Cabral H, Turner A, Zuckerman B. Relation between meconium concentration of the cocaine metabolite benzoylecgonine and fetal growth. J Pediatr. 1995 Apr; 126(4):636-8.View Related Profiles.

Zuckerman, Barry
Frank, Deborah
Cabral, Howard
Mirochnick, Mark

PMID: 7699548

Nachman SA, Mueller BU, Mirochnick M, Pizzo PA. High failure rate of dapsone and pentamidine as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1994 Nov; 13(11):1004-6. PMID: 7845719

Mirochnick M, Barnett E, Clark DF, McNamara E, Cabral H. Stability of chloroquine in an extemporaneously prepared suspension stored at three temperatures. Pediatr Infect Dis J. 1994 Sep; 13(9):827-8.View Related Profiles.

Barnett, Elizabeth
Cabral, Howard
Mirochnick, Mark

PMID: 7808855

Barnett ED, Pelton SI, Mirochnick M, Cooper ER. Dapsone for prevention of Pneumocystis pneumonia in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J. 1994 Jan; 13(1):72-4.View Related Profiles.

Barnett, Elizabeth
Cooper, Ellen
Mirochnick, Mark
Pelton, Stephen

PMID: 8170736

Needlman R, Zuckerman B, Anderson GM, Mirochnick M, Cohen DJ. Cerebrospinal fluid monoamine precursors and metabolites in human neonates following in utero cocaine exposure: a preliminary study. Pediatrics. 1993 Jul; 92(1):55-60.View Related Profiles.

Zuckerman, Barry
Mirochnick, Mark

PMID: 8516085

Mirochnick M, Michaels M, Clarke D, Breña A, Regan AM, Pelton S. Pharmacokinetics of dapsone in children. J Pediatr. 1993 May; 122(5 Pt 1):806-9.View Related Profiles.

Clarke, Diana
Mirochnick, Mark
Pelton, Stephen

PMID: 8496767

Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, Wilfert C, McKinney R, Crain MJ, Elkins MM, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993 Jan; 122(1):137-44.View Related Profiles.

Mirochnick, Mark
Pelton, Stephen

PMID: 8419601

Mirochnick M, Meyer J, Cole J, Herren T, Zuckerman B. Circulating catecholamine concentrations in cocaine-exposed neonates: a pilot study. Pediatrics. 1991 Sep; 88(3):481-5.View Related Profiles.

Zuckerman, Barry
Mirochnick, Mark

PMID: 1909023

Mirochnick MH, Miceli JJ, Kramer PA, Chapron DJ, Raye JR. Renal response to furosemide in very low birth weight infants during chronic administration. Dev Pharmacol Ther. 1990; 15(1):1-7. PMID: 2242705

Mirochnick MH, Miceli JJ, Kramer PA, Chapron DJ, Raye JR. Furosemide pharmacokinetics in very low birth weight infants. J Pediatr. 1988 Apr; 112(4):653-7. PMID: 3351693

Vintzileos AM, Campbell WA, Nochimson DJ, Weinbaum PJ, Mirochnick MH, Escoto DT. Fetal biophysical profile versus amniocentesis in predicting infection in preterm premature rupture of the membranes. Obstet Gynecol. 1986 Oct; 68(4):488-94. PMID: 3748497

Vintzileos AM, Campbell WA, Storlazzi E, Mirochnick MH, Escoto DT, Nochimson DJ. Fetal liver ultrasound measurements in isoimmunized pregnancies. Obstet Gynecol. 1986 Aug; 68(2):162-7. PMID: 3090490

Vintzileos AM, Campbell WA, Nochimson DJ, Weinbaum PJ, Escoto DT, Mirochnick MH. Qualitative amniotic fluid volume versus amniocentesis in predicting infection in preterm premature rupture of the membranes. Obstet Gynecol. 1986 Apr; 67(4):579-83. PMID: 3515258

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 159 publications over 36 distinct years, with a maximum of 14 publications in 2020

Bar chart showing 159 publications over 36 distinct years, with a maximum of 14 publications in 2020

Year	Publications
1986	3
1988	1
1990	1
1991	1
1993	3
1994	3
1995	1
1996	2
1997	1
1998	3
1999	7
2000	4
2001	3
2002	3
2003	3
2004	1
2005	4
2006	3
2007	2
2008	6
2009	3
2010	3
2011	9
2012	5
2013	4
2014	7
2015	5
2016	2
2017	4
2018	10
2019	11
2020	14
2021	12
2022	9
2023	5
2024	1

Media Mentions

Examining Adverse Pregnancy Outcomes in People Living with HIV

Managed Healthcare Executive 3/21/2023

Integrase Inhibitors During Pregnancy: Study Explores Safety and Efficacy

Infectious Diseases Consultant 3/7/2019

Studies Support Use Of Integrase Inhibitors In Pregnant Women With HIV

Healio 3/6/2019

IMPAACT Study on HIV Medications Taken During Pregnancy to Begin New Phase in 2019

Infectious Diseases Today 2/5/2019

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Neonatology

Contact for Mentoring:

771 Albany St
Boston MA 02118
Google Map

617.414.3754

Download vCard

Mirochnick's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (357) concept(s)

Media Mentions

Co-Authors

See all (17) people

Similar People

See all (60) people

Same Department

Search Department